Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 124 clinical trials
Efficacy and Safety of Rituximab in the Treatment of Good Prognosis Microscopic Polyangiitis (RITUXGOPRO)

The purpose of the study is to determine wether a rituximab-based treatment compared to standard therapy (glucocorticoid alone) in patients with microscopic polyangiitis without any bad prognosis marker increases the remission and reduces the relapse free survival rate.

  • 0 views
  • 22 Mar, 2022
  • 1 location
Intraorbital Injection Versus Oral Steroid in Anterior Idiopathic Orbital Inflammation

A multicenter randomised double-arm clinical trial, to compare safety and efficacy of oral versus intralesional injection of steroid in a group of patients suffering from idiopathic orbital inflammation is designed. Outcome measures include number of recurrences, duration of remission, and side effects.

  • 6 views
  • 08 Jul, 2021
  • 1 location
Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's)

Multi-center, randomized, double-blind, placebo-controlled trial to evaluate the efficacy of abatacept to achieve sustained glucocorticoid-free remission in patients with relapsing non-severe granulomatosis with polyangiitis (Wegener's) (GPA) . Participants will be randomized 1:1 to receive either abatacept 125 mg or placebo administered by subcutaneous injection once a week. Participants will continue …

remission
nasal discharge
anti-neutrophil cytoplasmic antibody
tooth decay
urinary sediment
  • 197 views
  • 18 May, 2022
  • 20 locations
Hydroxychloroquine in ANCA Vasculitis Evaluation

(ANCA) Vasculitis, a group of autoimmune diseases. Hydroxychloroquine and is an established, effective, safe and inexpensive therapy, widely used in other autoimmune diseases such as lupus and

  • 0 views
  • 26 Jan, 2021
  • 3 locations
Rituximab and Belimumab Combination Therapy in PR3 Vasculitis (COMBIVAS)

Mechanistic study to assess whether dual B-cell immunotherapy by co-administration of rituximab and belimumab will result in improvements in biological endpoints, functional outcomes and clinical status compared to rituximab with placebo.

rituximab
prednisolone
anti-neutrophil cytoplasmic antibody
microscopic polyangiitis
vasculitis
  • 19 views
  • 09 Feb, 2022
  • 1 location
Maintenance of ANCA Vasculitis Remission by Intermittent Rituximab Dosing (MAINTANCAVAS)

The purpose of this study is to determine the best management strategy to maintain remission in patients with ANCA vasculitis who have been treated with rituximab induced B cell depletion for at

  • 0 views
  • 23 Feb, 2022
  • 1 location
A Randomized Multicenter Study for Isolated Skin Vasculitis (ARAMIS)

Multi-center sequential multiple assignment randomized trial comparing the effectiveness of three different standard of care treatment options for patients with isolated skin vasculitis.

  • 194 views
  • 22 Mar, 2022
  • 9 locations
Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis (LoDoNaVasc)

of use in other conditions, and uncertainty about the mechanism of action study is needed in a diverse set of diseases, including vasculitis. The purpose of this clinical trial is to determine

necrotizing arteritis
anca
chest radiograph
myalgias
claudication
  • 196 views
  • 25 Mar, 2022
  • 2 locations
Exploring Durable Remission With Rituximab in Antineutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis (ENDURRANCE-1)

Rationale: Most recent insights in the treatment for patients with ANCA-associated vasculitis (AAV) have demonstrated that 'tailored' maintenance treatment with rituximab (RTX) is effective to

rituximab
cyclophosphamide
  • 0 views
  • 06 Feb, 2022
  • 1 location
Soluble CD95 Ligand Role in the Pathophysiology of Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis (VASC-FAS)

The study aims at defining the role of soluble CD95 Ligand in the physiopathology of a rare group of inflammatory diseases: ANCA associated vasculitis. Soluble CD95 Ligand might have a

  • 0 views
  • 02 Mar, 2022